Physician profile
Mohammed Saif
NPI 1275562415
$3,645.08
in general payments reported to CMS, 2019-2025
21 companies · $14.08 in 2025
The $14.08 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $390 · 2020: $140 · 2021: $469 · 2022: $1,876 · 2023: $499 · 2024: $256 · 2025: $14.08.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $755 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $754.67 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,550.52 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $337.47 | 2019-2023 | |
| Pfizer INC. | $315.14 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $249.78 | 2019-2022 | |
| Acadia Pharmaceuticals INC | $240.58 | 2023 | Nuplazid |
| Astrazeneca Pharmaceuticals Lp | $231.26 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $172.18 | 2019-2023 | Livalo, Seglentis |
| Novo Nordisk INC | $121.06 | 2019-2024 | Rybelsus, Ozempic |
| Amgen INC. | $94.87 | 2019-2025 | Otezla, Repatha, Repatha |
| Siemens Medical Solutions USA, INC. | $62.39 | 2023 | Acuson Redwood Diagnostic Ultrasound System |
| Merck Sharp & Dohme LLC | $54.89 | 2019-2022 | |
| Esperion Therapeutics, INC. | $43.48 | 2024 | Nexletol |
| Seqirus USA INC | $25.68 | 2019-2020 | |
| Eisai INC. | $22.24 | 2024 | |
| Amarin Pharma, INC. | $20.28 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biocryst US Sales Co., LLC | $20.16 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.07 | 2024 | Caplyta |
| Astellas Pharma US INC | $17.42 | 2024 | Veozah |
| Lilly USA, LLC | $16.18 | 2024 | Mounjaro |
| Daiichi Sankyo INC. | $15.73 | 2022 | |
| Medicure Pharma INC. | $14.70 | 2024 | Zypitamag |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammed Saif listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.